A detailed history of Vivo Capital, LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Vivo Capital, LLC holds 6,895,746 shares of TERN stock, worth $39.2 Million. This represents 8.42% of its overall portfolio holdings.

Number of Shares
6,895,746
Previous 6,182,992 11.53%
Holding current value
$39.2 Million
Previous $42.1 Million 36.58%
% of portfolio
8.42%
Previous 6.22%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.49 - $10.8 $4.63 Million - $7.7 Million
712,754 Added 11.53%
6,895,746 $57.5 Million
Q2 2024

Aug 14, 2024

SELL
$4.54 - $8.2 $2.16 Million - $3.89 Million
-475,000 Reduced 7.13%
6,182,992 $42.1 Million
Q4 2022

Feb 13, 2023

BUY
$4.62 - $10.18 $3.5 Million - $7.72 Million
758,620 Added 12.86%
6,657,992 $67.8 Million
Q3 2022

Nov 14, 2022

BUY
$1.87 - $6.42 $6.03 Million - $20.7 Million
3,224,239 Added 120.53%
5,899,372 $34.7 Million
Q1 2021

May 17, 2021

BUY
$17.13 - $27.25 $45.8 Million - $72.9 Million
2,675,133 New
2,675,133 $58.9 Million

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $214M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Vivo Capital, LLC Portfolio

Follow Vivo Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vivo Capital, LLC with notifications on news.